Idera Pharmaceuticals Reports Third Quarter Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces Expansion of Rare Disease Development Portfolio

-- Enrollment achieved in first two dose cohorts of Phase 1/2 Waldenstrom's trial
-- Myositis program advanced with specification of Phase 2 clinical trial plan in dermatomyositis
-- Rare disease portfolio expanded to include Duchenne muscular dystrophy; collaboration with leading Duchenne patient group announced

CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA ), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial results and business highlights for the third quarter of 2014. Key business highlights included significant progress with the enrollment of the Company's Phase 1/2 trial of IMO-8400 in Waldenström's macroglobulinema, advancement of a Phase 2 clinical trial plan for IMO-8400 in dermatomyositis, and an expansion of the Company's rare disease portfolio to include a research program in Duchenne muscular dystrophy (DMD).

"With a research program in Duchenne muscular dystrophy and a focused clinical development strategy in dermatomyositis, we have expanded and advanced our rare disease portfolio in diseases where there is strong scientific rationale for Toll-like receptor antagonism and an urgent need for new treatments," said Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera Pharmaceuticals. "In addition, we have enrolled patients in the second dose cohort in our Phase 1/2 trial of IMO-8400 in Waldenström's macroglobulinemia, based on a positive review of safety data from the first dose cohort."

Dr. Agrawal added, "Taken together, these updates represent important steps toward advancing our corporate strategy in genetically defined forms of B-cell lymphoma and rare diseases."

RECENT BUSINESS HIGHLIGHTS

Genetically Defined Forms of B-cell Lymphoma Program

Waldenström's Macroglobulemia

  • Idera completed enrollment of the 0.6 mg/kg dose cohort in the Company's Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia. An independent data review committee (DRC) reviewed four-week safety data and recommended that the Company advance the trial to the next dosage level. Enrollment in the 1.2 mg/kg dose cohort was initiated, and the Company has now achieved enrollment of a sufficient number of patients in this cohort to support DRC review of safety data in the fourth quarter. Pending a positive review of safety data, the Company plans to continue dose escalation to the 2.4 mg/kg dose cohort by year end.

MYD88 L265P-Positive Diffuse Large B-cell Lymphoma

  • The Company activated multiple clinical sites and expanded screening of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) harboring the MYD88 L265P oncogenic mutation in its Phase 1/2 clinical trial of IMO-8400 in DLBCL.
     
  • In addition, Idera completed initial development of a prototype companion diagnostic under a collaboration with Abbott Molecular. The Company plans to incorporate the diagnostic into ongoing screening for the MYD88 L265P oncogenic mutation in its Phase 1/2 clinical trial of IMO-8400 in patients with DLBCL.

Upcoming Oncology Data Presentations

  • Earlier this week, Idera announced plans to present clinical safety data from the IMO-8400 clinical development program at the American Society of Hematology (ASH) 2014 Annual Meeting in San Francisco from December 6-8. In addition, new preclinical data from studies of IMO-8400 in combination with rituximab in MYD88 L265P-positive B-cell lymphoma models will be presented at ASH 2014.

Rare Autoimmune Disease Program

Duchenne Muscular Dystrophy

  • This morning, the Company announced plans to collaborate with Parent Project Muscular Dystrophy (PPMD), a leading patient advocacy organization, to develop a potential non-steroid-based anti-inflammatory treatment using Idera's Toll-like receptor (TLR) antagonism technology. DMD is a rare, fatal muscle disorder affecting approximately 15,000 to 20,000 patients in the U.S. It is characterized by progressive muscle weakness, pulmonary and cardiac dysfunction, and death typically before age 30. Previously published independent research has shown that TLR 7 is up-regulated in DMD patients. 1 In a preclinical model of DMD, knockout of the gene for the MYD88 TLR adaptor protein led to significant improvements in skeletal and cardiac muscle function. In a separate study conducted by researchers from Children's National Health System and Idera, treatment with a TLR antagonist candidate led to a significant reduction of pro-inflammatory cytokines, a significant decrease in creatine kinase, and a significant increase in muscle strength in a preclinical DMD model. 2 Idera plans to collaborate with PPMD to expand preclinical studies and develop a clinical development strategy for a TLR antagonist candidate in DMD.

Dermatomyositis

  • Idera advanced plans for a Phase 2 clinical trial of IMO-8400 in dermatomyositis, a rare and severe inflammatory muscle disorder affecting approximately 25,000 patients in the U.S. Dermatomyositis is characterized by muscle weakness, joint pain, skin rash, and difficulty swallowing. Clinical planning has been supported by an ongoing collaboration with The Myositis Association, a leading patient advocacy organization, and an expert advisory committee formed by Idera earlier in 2014. The Company intends to have interactions with regulatory authorities regarding its clinical development strategy in early 2015, with the goal of initiating patient treatment in a Phase 2 clinical trial of IMO-8400 in dermatomyositis.

Pipeline Expansion

Phase 1 Trial of IMO-9200

  • The Company initiated patient dosing in a Phase 1 clinical trial of IMO-9200 in healthy volunteers, following acceptance for filing of an Investigational New Drug Application by the U.S. Food and Drug Administration. The Company expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015.
     
  • Idera scientists presented new preclinical data that showed IMO-9200 inhibited TLR-mediated immune responses in multiple disease models at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society Annual Meeting in San Diego in October 2014.

Gene Silencing Oligonucleotide Technology Platform

  • In addition, the Company advanced preclinical development of its gene silencing oligonucleotide (GSO) technology, a third generation antisense platform. GSOs are specifically designed to avoid the immunotoxicity observed with earlier generation technologies to enable improved therapeutic index. The Company plans to select two GSO drug candidates for further development in 2015.

THIRD QUARTER 2014 FINANCIAL RESULTS

As of September 30, 2014, Idera's cash, cash equivalents and investments totaled $58.3 million compared to $35.6 million as of December 31, 2013.

Net loss applicable to common stockholders for the three months ended September 30, 2014 was $9.6 million, or $0.11 per diluted share, compared to a net loss applicable to common stockholders of $5.0 million, or $0.11 per diluted share, for the same period in 2013. For the nine month period ended September 30, 2014, the Company's net loss applicable to common stockholders was $27.1 million, or $0.33 per diluted share, compared to a net loss applicable to common stockholders of $14.7 million, or $0.40 per diluted share, for the same period in 2013.

Research and development expenses for the three months ended September 30, 2014 totaled $6.7 million compared to $2.5 million for the same period in 2013. For the nine month period ended September 30, 2014, research and development expenses totaled $19.2 million compared to $6.8 million for the same period in 2013.

General and administrative expenses for the three months ended September 30, 2014 totaled $2.9 million compared to $2.2 million for the same period in 2013. For the nine-month period ended September 30, 2014, general and administrative expenses totaled $7.6 million compared to $5.3 million for the same period in 2013.

WEBCAST AND CONFERENCE CALL

Idera will host a conference call today at 8:00 a.m. EST to discuss third quarter 2014 financial results and corporate highlights. The live webcast, including reference slides, can be accessed under "Investor Events" in the Investors and Media section of the Company's website at www.iderapharma.com . To access the conference call, dial 1-866-202-0886 (domestic) or 1-617-213-8841 (international) and provide the access code 74052148. Following the event, an archive of the webcast will be available in the Investors and Media section of the Company's website for 90 days.

ABOUT IDERA PHARMACEUTICALS

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com .  

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company's strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether results obtained in preclinical studies and clinical trials such as the results described in this release will be indicative of the results that will be generated in future clinical trials; whether products based on Idera's technology will advance into or through the clinical trial process when anticipated or at all or warrant submission for regulatory approval; whether such products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations will be successful; and such other important factors as are set forth under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2014. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

REFERENCES

1 Chen Y.-W., et al. Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy. Neurology. 2005;65;826-834.

2 Henriques A, et al. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet. 2014 May 15;23(10):2604-17.

Idera Pharmaceuticals, Inc.
Condensed Statements of Operations
(In thousands, except per share data)
         
  Three Months Ended Nine Months Ended
  September 30, September 30,
  2014 2013 2014 2013
  (Unaudited)
Revenues $30 $7 $71 $43
         
Operating Expenses        
         
Research & Development 6,678 2,510 19,248 6,835
         
General & Administrative 2,873 2,179 7,646 5,305
         
Total Operating Expenses 9,551 4,689 26,894 12,140
         
Loss from Operations (9,521) (4,682) (26,823) (12,097)
         
Other, net 66 (56) 99 (39)
         
Net Loss (9,455) (4,738) (26,724) (12,136)
         
Loss on Extinguishment of Convertible Preferred Stock and Preferred Stock Dividends 119 278 422 2,587
         
Net Loss Applicable to Common Stockholders $(9,574) $(5,016) $(27,146) $(14,723)
         
Basic and Diluted Net Loss Per Common Share Applicable to Common Stockholders $(0.11) $(0.11) $(0.33) $(0.40)
         
Shares Used in Computing Basic and Diluted Net Loss Per Common Share Applicable to Common Stockholders 84,527 45,720 81,200 37,203
 
Idera Pharmaceuticals, Inc.
Condensed Balance Sheet Data
(In thousands)
  September 30, December 31,
  2014 2013
  (Unaudited)  
     
Cash, Cash Equivalents & Investments $58,280 $35,592
     
Other Assets $2,352 $1,275
     
Total Assets $60,632 $36,867
     
Total Liabilities $7,811 $4,415
     
Total Stockholders' Equity $52,821 $32,452
     
Total Liabilities & Stockholders' Equity $60,632 $36,867

INVESTOR AND MEDIA CONTACT: Jim Baker Executive Director, Corporate Affairs (617) 679-5516

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 92

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 22

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 14

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 21

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 286

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Canadian Solar's Storage Deal Has Real Staying Power

Updated Category News Views 18

Five battery projects and 22-year service contracts are the sort of details that make me stop squinting at renewable-energy headlines. Canadian Solar's e-STORAGE unit has signed agreements with X-ELIO to supply 590 MW and 1.43 GWh of battery energy storage across four Texas projects and one in New South Wales, Australia. That is not a vague memorandum, not a pilot, and...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 11

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 46

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering Leo XIV: Insights Into Our First American Pope

Updated Category News Views 427

Introducing Leo XIV: The First American Pope Exciting news resonates across the Catholic community with the election of Leo XIV, the first American pope. EWTN Publishing is preparing to unveil the first comprehensive portrait of this monumental figure, appropriately titled LEO XIV: Portrait of the First American Pope. This intriguing book promises to offer valuable...

Continue Reading
nextSource Elevates Leadership with New COO to Enhance Growth

Updated Category News Views 144

nextSource Strengthens Leadership with Ronald LeVan as COO nextSource has made a significant move in its leadership by appointing Ronald LeVan as the new Chief Operating Officer. This change is part of the company’s strategic vision aimed at elevating client service standards and ensuring long-term growth. This appointment reflects a commitment to an innovative and...

Continue Reading
KBR Extends EPCM Partnership with Basra Oil Company Today

Updated Category News Views 193

KBR Renews Contract with Basra Oil Company KBR (NYSE: KBR) has exciting news to share—the company has successfully secured a two-year renewal of its engineering, procurement, and construction management (EPCM) contract with Basra Oil Company for operations at the Majnoon Oil Field. This extension strengthens KBR's position in the region and reflects the confidence BOC...

Continue Reading
Opendoor Stock Sees Surge Following CEO's Share Purchase

Updated Category News Views 174

Opendoor Technologies Inc. Stock Performance Opendoor Technologies Inc. (NASDAQ: OPEN) has witnessed a significant increase in its stock price as recent developments unfold. CEO Kaz Nejatian made a bold move by announcing his intent to purchase $1 million worth of company shares, which has positively influenced investor sentiment. CEO's Announcement Boosts Investor...

Continue Reading
Dr. Ellen Marmur Joins Forces with MedSpa Partners for Growth

Updated Category News Views 480

Dr. Ellen Marmur Joined MedSpa Partners to Enhance Aesthetic Care - MSP Begins the Year with the Addition of One of the Industry's Most Respected Practices - MedSpa Partners Inc. ("MSP") is excited to announce the recent partnership with Dr. Ellen Marmur and her esteemed team at Marmur Medical. With a dedicated focus on elevating the medical aesthetics landscape, this...

Continue Reading